Search

Author/Creator Bonomi, Maria

1. A Phase II Study of PF‐03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. Issue 11 (November 2016)

Authors:
Wheatley‐Price, Paul; Chu, Quincy; Bonomi, Maria; Seely, Jean; Gupta, Ashish; Goss, Glenwood; Hilton, John; Feld, Ronald; Lee, Christopher W.; Goffin, John R; Maksymiuk, Andrew; Murray, Nevin; Hagerman, Linda; Bradbury, Penelope A.
Journal:
Journal of thoracic oncology
Issue:
Volume 11:Issue 11(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10 (October 2021)

Authors:
Pinto, Carmine; Zucali, Paolo Andrea; Pagano, Maria; Grosso, Federica; Pasello, Giulia; Garassino, Marina Chiara; Tiseo, Marcello; Soto Parra, Hector; Grossi, Francesco; Cappuzzo, Federico; de Marinis, Filippo; Pedrazzoli, Paolo; Bonomi, Maria; Gianoncelli, Letizia; Perrino, Matteo; Santoro, Arma...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 10(2021)
Page Start:
1438
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy. (21st September 2017)

Authors:
Zucali, Paolo Andrea; Lopci, Egesta; Ceresoli, Giovanni Luca; Giordano, Laura; Perrino, Matteo; Ciocia, Gianluigi; Gianoncelli, Letizia; Lorenzi, Elena; Simonelli, Matteo; De Vincenzo, Fabio; Setti, Lucia Rebecca; Bonifacio, Cristiana; Bonomi, Maria; Bombardieri, Emilio; Chiti, Arturo; Santoro, A...
Journal:
Cancer medicine
Issue:
Volume 6:Number 10(2017:Oct.)
Page Start:
2287
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. Issue 1 (January 2015)

Authors:
Bria, Emilio; Massari, Francesco; Maines, Francesca; Pilotto, Sara; Bonomi, Maria; Porta, Camillo; Bracarda, Sergio; Heng, Daniel; Santini, Daniele; Sperduti, Isabella; Giannarelli, Diana; Cognetti, Francesco; Tortora, Giampaolo; Milella, Michele
Journal:
Critical reviews in oncology/hematology
Issue:
Volume 93:Issue 1(2015)
Page Start:
50
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗